Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VRN Stock Forecast 2025-2026
$6.01
Current Price
$3.69B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VRN Price Targets
+31.3%
To High Target of $7.89
+31.3%
To Median Target of $7.89
+31.3%
To Low Target of $7.89
VRN Price Momentum
+4.5%
1 Week Change
+4.7%
1 Month Change
-30.9%
1 Year Change
+16.9%
Year-to-Date Change
-34.2%
From 52W High of $9.14
+36.9%
From 52W Low of $4.39
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Veren (VRN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VRN and similar high-potential opportunities.
Latest VRN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, VRN has a bullish consensus with a median price target of $7.89 (ranging from $7.89 to $7.89). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $6.01, the median forecast implies a 31.3% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRN Analyst Ratings
9
Buy
0
Hold
0
Sell
VRN Price Target Range
Low
$7.89
Average
$7.89
High
$7.89
Current: $6.01
Latest VRN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 1, 2024 | RBC Capital | Michael Harvey | Outperform | Maintains | $10.00 |
| Oct 18, 2024 | Raymond James | Luke Davis | Strong Buy | Initiates | $13.00 |
| Jul 12, 2024 | Scotiabank | Sector Outperform | Maintains | $15.00 |
Veren Inc. (VRN) Competitors
The following stocks are similar to Veren based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Veren Inc. (VRN) Financial Data
Veren Inc. has a market capitalization of $3.69B with a P/E ratio of 18.2x. The company generates $2.85B in trailing twelve-month revenue with a 6.9% profit margin.
Revenue growth is +5.6% quarter-over-quarter, while maintaining an operating margin of +15.1% and return on equity of +4.2%.
Valuation Metrics
Market Cap
$3.69B
Enterprise Value
$4.83B
P/E Ratio
18.2x
PEG Ratio
7.9x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
+5.6%
Gross Margin
+55.0%
Operating Margin
+15.1%
Net Margin
+6.9%
EPS Growth
+12.2%
Financial Health
Cash/Price Ratio
+0.5%
Current Ratio
0.6x
Debt/Equity
45.3x
ROE
+4.2%
ROA
+3.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Veren Inc. (VRN) Business Model
About Veren Inc.
What They Do
Develops innovative therapies for unmet medical needs.
Business Model
Veren Inc. generates revenue through the discovery and development of novel therapies, leveraging advanced biotechnological research. The company collaborates with academic institutions and pharmaceutical companies to enhance its drug development processes, thus creating a robust pipeline of drug candidates targeted at rare and complex diseases.
Additional Information
Headquartered in a major biotech hub, Veren Inc. is influential in the biotechnology sector, contributing to market trends and attracting investor interest. Its focus on gene editing, personalized medicine, and monoclonal antibody development positions it strongly within the industry.
Company Information
Sector
Energy
Industry
Oil & Gas E&P
Employees
746
CEO
Mr. Craig Bryksa
Country
Canada
IPO Year
2003
Website
www.vrn.comVeren Inc. (VRN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is Constellation Energy Corporation (CEG) Outperforming Other Oils-Energy Stocks This Year?
Here is how Constellation Energy Corporation (CEG) and Veren (VRN) have performed compared to their sector so far this year.
May 09, 2025
By Zacks Equity Research
Tale of the Tape
Plains All American to Report Q1 Earnings: How to Play the Stock?
PAA stock's first-quarter earnings will benefit from its fee-based contracts, contributions from acquired and organic assets.
May 08, 2025
By Jewel Saha
Analyst Blog
Suncor Energy (SU) Q1 Earnings and Revenues Beat Estimates
Suncor Energy (SU) delivered earnings and revenue surprises of 5.81% and 3.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
WHITECAP RESOURCES INC. AND VEREN INC.
3 days ago
Quick Summary
Whitecap Resources Inc. will acquire Veren Inc. following a court ruling. Veren shareholders will receive 1.05 Whitecap shares for each share of Veren they hold.
Why It Matters
The court's approval of Whitecap's acquisition of Veren indicates potential growth through consolidation, impacting share values and investor confidence in both companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Wall Street Analysts Think Veren (VRN) Could Surge 34.97%: Read This Before Placing a Bet
7 days ago
Quick Summary
Wall Street analysts suggest a 35% potential upside for Veren (VRN), supported by positive earnings estimate revisions, despite questions about the reliability of price targets.
Why It Matters
The 35% upside in price targets suggests significant growth potential for Veren (VRN), while positive earnings revisions may boost investor confidence and drive the stock higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Veren (VRN) is expected to potentially exceed earnings expectations in its upcoming report, driven by favorable key factors.
Why It Matters
Veren's potential earnings beat could boost stock prices and investor confidence, indicating strong performance and possibly attracting more investment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
An investor sold oil stocks to acquire a large position in Whitecap Resources, citing strong Q1 results, production exceeding guidance, and a sustainable 9% dividend yield post-merger.
Why It Matters
The Whitecap-Veren merger boosts efficiency, lowers costs, and supports a sustainable dividend, enhancing Whitecap's attractiveness amid volatile oil markets.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Investors should monitor SLB, IMO, and VRN as potential dividend stocks for 2025.
Why It Matters
The mention of SLB, IMO, and VRN as promising dividend stocks indicates potential income opportunities and growth prospects for investors looking ahead to 2025.
Source: Zacks Investment Research
Market Sentiment:
Positive
Wall Street Analysts See a 27.59% Upside in Veren (VRN): Can the Stock Really Move This High?
1 month ago
Quick Summary
Wall Street analysts project a 27.6% potential upside for Veren (VRN), supported by positive earnings estimate revisions.
Why It Matters
The 27.6% upside potential from analyst price targets and positive earnings revisions suggest strong growth expectations for Veren (VRN), impacting investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About VRN Stock
What is Veren Inc.'s (VRN) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Veren Inc. (VRN) has a median price target of $7.89. The highest price target is $7.89 and the lowest is $7.89.
Is VRN stock a good investment in 2025?
According to current analyst ratings, VRN has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRN stock?
Wall Street analysts predict VRN stock could reach $7.89 in the next 12 months. This represents a 31.3% increase from the current price of $6.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Veren Inc.'s business model?
Veren Inc. generates revenue through the discovery and development of novel therapies, leveraging advanced biotechnological research. The company collaborates with academic institutions and pharmaceutical companies to enhance its drug development processes, thus creating a robust pipeline of drug candidates targeted at rare and complex diseases.
What is the highest forecasted price for VRN Veren Inc.?
The highest price target for VRN is $7.89 from at , which represents a 31.3% increase from the current price of $6.01.
What is the lowest forecasted price for VRN Veren Inc.?
The lowest price target for VRN is $7.89 from at , which represents a 31.3% increase from the current price of $6.01.
What is the overall VRN consensus from analysts for Veren Inc.?
The overall analyst consensus for VRN is bullish. Out of 3 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.89.
How accurate are VRN stock price projections?
Stock price projections, including those for Veren Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 5:37 AM UTC